Astellas is committed to providing timely and accurate information about our business, science and products. This section offers global resources for investors, journalists and media professionals. News and resources from our local affiliates can be viewed in the Local news section. If you are not an investor or journalist, click here.
| Su | Mo | Tu | We | Th | Fr | Sa |
|---|---|---|---|---|---|---|
| Su | Mo | Tu | We | Th | Fr | Sa |
|---|---|---|---|---|---|---|
Tokyo, April 26, 2011 – Asteallas Pharma Inc. (TOKYO: 4503, “Astellas”) expresses its deepest sympathy for those who have lost their lives and been displaced by the Eastern Japan Earthquake,...
Read more about Astellas Assesses the Impact of the Eastern Japan Earthquake (4th Notice)
Tokyo, April 20, 2011 - Astellas Pharma Inc. (TOKYO:4503,“Astellas”) announced that a new dosage form of Vesicare® (generic name: solifenacin succinate), the orally disintegrating tablet...
Read more about Astellas Launches Orally Disintegrating Tablet "Vesicare® OD" in Japan
Tokyo, April 5, 2011 - Astellas Pharma Inc. (“Astellas”, TSE: 4503) expresses its deepest sympathy for those who have lost their lives and been displaced by the Eastern Japan Earthquake, which...
Read more about Astellas Assesses the Impact of the Eastern Japan Earthquake (3rd Notice)
Tokyo, March 30, 2011 - Astellas Pharma Inc. (“Astellas”; headquarters: Tokyo; President and CEO: Masafumi Nogimori) and Pfizer Japan Inc. (“Pfizer”; Headquarters: Tokyo; President: Ichiro...
Tokyo, March 25, 2011, Astellas Pharma Inc. (“Astellas”; headquarters: Tokyo; President and CEO: Masafumi Nogimori) announced today that it has established Astellas Pharma d.o.o. in Slovenia....
Read more about Astellas Establishes a new Affiliate In South East Europe
Tokyo, March 23, 2011 - Astellas Pharma Inc. (“Astellas”, TSE: 4503) expresses its deepest sympathy for those who have lost their lives and been displaced by the Tohoku Earthquake, which...
Read more about Astellas Assesses the Impact of the Tohoku Earthquake (2nd Notice)
Tokyo, March 17, 2011 - Astellas Pharma Inc. (“Astellas”; headquarters: Tokyo; President and CEO: Masafumi Nogimori) today announced that it has exercised a buy-out option to acquire all of...
Read more about Astellas Pharma Inc.: Exercises Buy-Out Option for Perseid
Tokyo, March 16, 2011 - Astellas Pharma Inc. (“Astellas”; headquarters: Tokyo; President and CEO: Masafumi Nogimori) announced that OSI Pharmaceuticals, Inc. (a subsidiary of Astellas),...
Read more about OSI, Genentech, Pfizer and Teva Reach Settlement Agreement in Tarceva® Patent Case
Tokyo, March 15, 2011 - Astellas Pharma Inc. (“Astellas”, TSE: 4503) is currently assessing the impact of the Tohoku Earthquake upon its various facilities and provides details of current...
Read more about Astellas Assesses the Impact of the Tohoku Earthquake
Tokyo, March 14, 2011 - Astellas Pharma Inc. (“Astellas”; headquarters: Tokyo; President and CEO: Masafumi Nogimori) announced today that it submitted a market authorization application for an...
Tokyo – February 16, 2011 – Astellas Pharma Inc. (TSE:4503,”Astellas”) announced today that its affiliate, Astellas Pharma US, Inc.(“Astellas Pharma US”) exercised its right under its...
Read more about Astellas to Assume Full Commercial Responsibility for VESIcare®
Tokyo, February 15, 2011 - Astellas Pharma Inc. (“Astellas”; headquarters: Tokyo; President and CEO: Masafumi Nogimori) announced that it withdrew a market authorization application for...
Follow us
